Many preclinical studies targeting Her2+ tumor cells in glioblastoma, rhabdomyosarcoma, and breast cancer provide evidence of their potent cytotoxic effects and lower toxicity profiles. This evidence concerns the gene ERBB2 and breast carcinoma.